travoprost profile

Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5282226
CHEMBL ID	1200799
CHEBI ID	746859
SCHEMBL ID	93818
MeSH ID	M0403483

Synonym
AC-6103
(((1r)-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(1r-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
travatan z
al-6221
5-heptenoic acid, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (5z)-
travatan
(+)-fluprostenol isopropyl ester
travoprost [usan]
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (1r-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-
travatanz
travoprost
DB00287
isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
travatan (tn)
D01964
157283-68-6
travoprost (jan/usp/inn)
CHEBI:746859 ,
travoprostum
propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
CHEMBL1200799
otx-tp
nsc-760366
propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S3738
unii-wj68r08kx9
travoprost [usan:usp:inn:ban]
wj68r08kx9 ,
nsc 760366
izba
AM84515
gtpl7102
propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
travoprost [orange book]
travoprost component of duotrav
travoprost [mart.]
travoprost [inn]
duotrav component travoprost
travoprost [usp-rs]
travoprost [mi]
travoprost [jan]
isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-((.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
(1r-(1.alpha.(z),2.beta.(1e,3r*),3.alpha.,5.alpha.))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
travoprost [vandf]
travoprost [usp monograph]
travoprost [who-dd]
travoprost [ema epar]
HY-B0584
SCHEMBL93818
(z)-isopropyl 7-((1r,2r)-3,5-dihydroxy-2-((s,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
J-502633
isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r,e)-3-hydroxy-4-(3-(trifluoromethyl)-phenoxy)-but-1-enyl)-cyclopentyl)-hept-5-enoate
(z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl) phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
(z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
travaprost
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid 1-methyethyl ester
AKOS024458039
sr-01000942266
SR-01000942266-1
EX-A1772
bdbm50248302
DTXSID80896948 ,
BS-15509
Q2193376
sr-01000946860
SR-01000946860-1
5-heptenoic acid, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-, 1-methylethyl ester, (5z)-
CCG-269692
NCGC00346741-02
(z)-isopropyl7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
travoprostintermediates
EN300-21831206
travoprost in bulk
fluprostenol isopropyl ester;al6221;flu-ipr
travoprost ophthalmic solution, 0.004%
travoprost ophthalmic solution usp, 0.004%travoprost
dtxcid401326382
propan-2-yl (5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
travoprost (usp monograph)
travoprost (mart.)
isopropyl (5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-(3- (trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoate
travoprost (usan:usp:inn:ban)
travoprost ophthalmic solution
s01ee04
travoprost ophthalmic solution usp, 0.004%
isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
travoprost ophthalmic
5-heptenoic acid, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester,(5z)-
travoprost (usp-rs)

Excerpt	Reference	Relevance
"Travoprost is a synthetic prostaglandin F2α analogue used in treatment of glaucoma. "	( Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties. Ismail, A; Nasr, M; Sammour, O, 2020)	2.23
"Travoprost is a prostaglandin analog used in the treatment of open-angle glaucoma. "	( Hypertrichosis of the upper cheek area associated with travoprost treatment of glaucoma. Olver, JM; Ortiz-Perez, S, )	1.82
"Travoprost BAK-free is an effective option for IOP reduction while avoiding BAK exposure."	( Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Coote, M; Denis, P; Gandolfi, S; Goldberg, I; Paredes, T; Pillai, MR; Stalmans, I; Volksone, L; Wells, A, )	1.2
"Travoprost is a synthetic ester prodrug of a prostaglandin F(2alpha) analogue used in the treatment of open-angle glaucoma and ocular hypertension. "	( Travoprost. Jarvis, B; Waugh, J, 2002)	3.2
"Travoprost is a safe drug, with local side effects including hyperemia, eyelash growth and iris color change."	( Travoprost: a potent ocular hypotensive agent. Al-Jazzaf, AM; DeSantis, L; Netland, PA, 2003)	2.48
"Travoprost is a promising ocular hypotensive prostaglandin FP derivative that has the ocular hypotensive efficacy of PGF2alpha isopropyl ester but with less severe ocular side effects."	( Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. Dean, TR; Desantis, L; Hellberg, MR; McLaughlin, MA; Sallee, VL; Sharif, NA; Zinke, PW, 2001)	1.34
"Travoprost is a very stable compound, maintaining its efficacy following exposure to extremely low and high temperatures, repeated freezing and thawing and exposure to light."	( Travoprost--a new prostaglandin analogue for the treatment of glaucoma. Whitson, JT, 2002)	2.48

Excerpt	Reference	Relevance
"Travoprost has been widely used for the treatment of patients with open-angle glaucoma (OAG) or ocular hypertension (OH). "	( Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension. Chen, XM; Ge, J; Li, B; Sun, XH; Wang, NL; Wang, ZX; Wu, LL; Zhao, JL, 2010)	2.05
"Travoprost has similar effect as latanoprost in reducing the IOP in glaucoma patients with relatively low IOPs. "	( Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Sawada, A; Takatsuka, N; Yamamoto, T, 2012)	2.08
"Travoprost has demonstrated preferential affinity and full agonist activity for the FP receptor in the nanomolar range, with no meaningful affinity or activity at other receptors."	( Travoprost: a potent ocular hypotensive agent. Al-Jazzaf, AM; DeSantis, L; Netland, PA, 2003)	2.48
"Travoprost without BAK has similar IOP-lowering efficacy and safety compared with travoprost preserved with BAK. "	( Duration of IOP reduction with travoprost BAK-free solution. Dubiner, HB; Gross, RL; Ochsner, KI; Peace, JH; Smith, SE; Walters, TR; Weiss, MJ, )	1.86

Excerpt	Reference	Relevance
"Travoprost can increase activity of MMP1/2 gradually."	( Impact of combination use of 0.004% travoprost and 2% pilocarpine on matrix metalloproteinases synthesized by rabbit ciliary muscle: a pilot study. Zhang, SH; Zhao, JL, 2013)	1.39
"Travoprost seems to lower IOP by increasing trabecular outflow facility. "	( Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. Bergamini, MV; Camras, CB; Dickerson, JE; Fan, S; Landry, TA; Toris, CB; Zhan, G, 2007)	2.17
"Travoprost may cause significantly short-term conjunctival hyperaemia even after a single dose in the eyes of healthy African subjects."	( Conjunctival hyperaemia and other ocular adverse effects on healthy African subjects after single dosing with 0.004% Travoprost. Adedapo, AD; Adeoti, CO; Ashaye, AO; Olusanya, BA, 2007)	1.27
"Travoprost produced a lower incidence of ocular irritation than PGF20 isopropyl ester at a dose of 1 microg in the New Zealand albino (NZA) rabbit."	( Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. Dean, TR; Desantis, L; Hellberg, MR; McLaughlin, MA; Sallee, VL; Sharif, NA; Zinke, PW, 2001)	1.34

Excerpt	Reference	Relevance
"In travoprost-treated eyes, a statistically significant correlation between SC area and IOP is observed (r = -0.2817; P = 0.0004)."	( Expansion of Schlemm's canal by travoprost in healthy subjects determined by Fourier-domain optical coherence tomography. Chen, J; Chen, X; Huang, H; Sun, X; Zhang, S, 2013)	1.19
"Travoprost treatment leads to SC lumen expansion accompanied by a drop of IOP in the healthy eye, likely as a result of the enhancement of pressure sensitive trabecular meshwork outflow induced by travoprost."	( Expansion of Schlemm's canal by travoprost in healthy subjects determined by Fourier-domain optical coherence tomography. Chen, J; Chen, X; Huang, H; Sun, X; Zhang, S, 2013)	1.39
"Travoprost-treated patients had a smaller predicted change in visual field defect score (VFDS) than latanoprost-treated patients and timolol-treated patients, and significantly fewer were expected to demonstrate visual field progression."	( Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Covert, DW; Halpern, MT; Robin, AL, 2002)	1.36
"Travoprost-treated eyes showed a significant (P<0.001) decrease in daytime IOP compared with baseline (26%) or to vehicle-treated eyes (22%), and an increase in daytime outflow facility (P=0.001; 64%). "	( Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. Bergamini, MV; Camras, CB; Dickerson, JE; Fan, S; Landry, TA; Toris, CB; Zhan, G, 2007)	2.17
"Travoprost-treated patients' IOP levels were reduced 8.7 and 8.1 mm Hg at 8 and 10 AM, respectively."	( The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. Gultekin, S; Sahin, A; Yildirim, N, )	1.11
"Treatment with travoprost with sofZia significantly lowered mean diurnal and nocturnal IOP levels from baseline (diurnal 18.1 ± 3.9 to 15.3 ± 3.3 mm Hg; nocturnal 20.6 ± 3.6 to 19.4 ± 3.4 mm Hg, P < .01 for both). "	( The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure. Kahook, MY; Seibold, LK, 2014)	1.03
"Treatment with travoprost, 0.004%, was commenced at week 3 in the trial eye and at week 4 in the fellow eye."	( Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication. King, AJ; Rotchford, AP, 2016)	0.77
"Treatment with travoprost did not affect CCT."	( The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes. Bafa, M; Georgopoulos, G; Mihas, C; Papaconstantinou, D; Stavrakas, P; Vergados, I, 2011)	0.71
"Treatment with travoprost decreased IOP significantly and was associated with CCT thinning, which had little or no effect on actual IOP decrease. "	( Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Brady, M; Ennis, M; Gordon, KD; Harasymowycz, PJ; Papamatheakis, DG, 2007)	1.01

Excerpt	Reference	Relevance
" Adverse events were recorded at each visit."	( Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Castillo, A; Fernandez-Vidal, A; Garcia-Feijoo, J; Garcia-Sanchez, J; Martinez-de-la-Casa, JM; Mendez-Hernandez, C, 2004)	0.61
"To describe the adverse effect of abdominal cramp caused by travoprost ophthalmic solution in a glaucoma patient."	( Abdominal cramp as an adverse effect of travoprost. Lee, YC, 2005)	0.84
" Based on the findings of dechallenge and rechallenge procedures, abdominal cramp should be considered a certain adverse effect of travoprost according to the WHO classification."	( Abdominal cramp as an adverse effect of travoprost. Lee, YC, 2005)	0.8
" The impact on cellular viability and apoptosis in the same cell line was evaluated, to address the possible proinflammatory and/or toxic origin of the most frequent clinical impairments induced by prostanoids (i."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.56
"TNFalpha induced or stimulated expression of the three inflammatory markers, whereas the PGF2alpha, latanoprost, travoprost, and bimatoprost solutions did not induce an increase in these markers and even produced a marked reduction of ICAM-1 and PECAM-1 expression in those solutions most concentrated in BAC, thus suggesting a toxic phenomenon in cellular membranes induced by the preservative rather than the medication itself."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.77
" The adverse event profile for Trav/Tim was comparable to Trav or Tim alone."	( The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey, HS; Bergamini, MV; Flowers, BE; Landry, TA; Mallick, S; Orengo-Nania, S; Samples, J, 2005)	0.63
" The clinical results that Trav/Tim was safe and well tolerated with an incidence of adverse events was comparable to the results of Trav or Tim alone."	( The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey, HS; Bergamini, MV; Flowers, BE; Landry, TA; Mallick, S; Orengo-Nania, S; Samples, J, 2005)	0.63
" The most frequent ocular adverse event was hyperemia that occurred in 14."	( Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Bergamini, MV; Henry, JC; Katz, GJ; Landry, TA; Lewis, RA; Mallick, S; Robertson, SM; Schuman, JS; Sullivan, EK; Wells, DT, 2005)	0.59
" The most important adverse events for the prostaglandin derivatives were conjunctival hyperemia, eyelashes pigmentation and growth, iris pigmentation."	( Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Antohi, I; Chiseliţă, D; Danielescu, C; Medvichi, R, 2005)	0.57
" Both volunteered and elicited reports of adverse events were collected; all patients who were randomized and received > or =1 dose of study drug were included in the safety analysis."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.56
" Adverse events related to therapy were mild in nature, and there were no statistically significant differences between the 2 treatment groups."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.56
" Common adverse events were mild and included ocular hyperaemia, dysgeusia and eye irritation."	( Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Franks, W, 2006)	0.56
" There was no significant difference for any adverse event between groups (p>0."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.35
" Adverse events and the number of patients discontinued owing to adverse events were similar for both treatment groups."	( Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. Bergamini, MV; Dickerson, JE; Hua, SY; James, JE; Katz, GJ; Landry, TA; Lewis, RA; Montgomery, DB; Sullivan, EK; Weiss, MJ; Wells, DT, 2007)	1.78
" Treatment-related adverse events were mild in both groups."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.37
"5% fixed combination ophthalmic solution is an effective treatment for reducing IOP and it is safe and well-tolerated in patients with OAG or OH."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.37
" Adverse effects were assessed and conjunctival hyperemia was graded using a standardized scale."	( Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. Aung, T; Ho, CL; Hoh, ST; Istiantoro, VW; Kumar, RS; Oen, FT, )	0.37
"We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost."	( Comparison of ocular surface side effects of topical travoprost and bimatoprost. Alagöz, G; Bayer, A; Boran, C; Elçioğlu, M; Kükner, A; Serin, D, 2008)	0.82
" Safety measures included adverse events, biomicroscopy, visual acuity, heart rate, and blood pressure."	( Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. Blini, M; Curatola, MR; David, A; Merlo, G; Radaelli, R; Ratiglia, R; Rossi, GC; Trabucchi, G, 2009)	0.62
" No drug related serious adverse events were reported during the study."	( Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. Blini, M; Curatola, MR; David, A; Merlo, G; Radaelli, R; Ratiglia, R; Rossi, GC; Trabucchi, G, 2009)	0.62
" This retrospective study found travoprost to have minimal adverse events in children and to reduce IOP in select cases of pediatric glaucoma."	( Travoprost in children: adverse effects and intraocular pressure response. Enyedi, LB; Freedman, SF; Schotthoeffer, EO; Yanovitch, TL, 2009)	2.08
"To document patient/physician perceptions of adverse effects and their relationship to medication changes among patients prescribed prostaglandin analogs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Frequency of adverse effects noted by physicians and associations with medication change decisions were examined in charted data."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Adverse effects were the second most common reasons noted by physicians for switching medications after lack of efficacy (19% vs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
"Ocular adverse effects, particularly hyperemia, negatively affect patient continuation with therapy and switching."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
"Latanoprost, travoprost, and bimatoprost are prostaglandin or prostamide-type ocular hypotensive medications, all of which are effective and safe for lowering intraocular pressure (IOP)."	( Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). Ahmed, II; Birt, CM; Buys, YM; Trope, GE, 2010)	0.73
" No treatment-related serious adverse events were reported in this study."	( Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension. Chen, XM; Ge, J; Li, B; Sun, XH; Wang, NL; Wang, ZX; Wu, LL; Zhao, JL, 2010)	0.61
" Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension."	( Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension. Chen, XM; Ge, J; Li, B; Sun, XH; Wang, NL; Wang, ZX; Wu, LL; Zhao, JL, 2010)	1.52
" We present 2 cases of a newly described side effect of both these topical agents in terms of periorbital fat atrophy."	( Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Ghazi-Nouri, S; Jayaprakasam, A, 2010)	0.36
" No serious adverse event was found in both the groups."	( A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. Gao, YX; Huang, P; Li, B; Wang, ZX; Wu, LL, 2011)	0.6
"004% once daily is safe and well tolerated in PAC or PACG patients."	( A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. Gao, YX; Huang, P; Li, B; Wang, ZX; Wu, LL, 2011)	0.6
" The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11."	( Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Bae, K; Iwamoto, Y; Kitazawa, Y; Kotake, S; Sasaki, N; Smith, P, 2011)	1.81
" The gastro-intestinal effects are among the most reported adverse effects upon topical application of PGAs."	( Possible mechanism for the gastro-intestinal adverse effects upon topical application of Prostaglandin F₂α analogs. Cai, S; Li, X; Liu, X; Yan, N; Zhou, X, 2013)	0.39
" Mild ocular redness was the commonest side effect in both the groups but was not significant in either group."	( Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Chander, A; Kapoor, H; Thomas, S, )	0.37
"Both drugs lowered IOP effectively but bimatoprost showed a greater reduction in the mean IOP than did travoprost at 12 weeks and both are safe for ocular use."	( Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Chander, A; Kapoor, H; Thomas, S, )	0.58
" The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group."	( Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension. Andreić, V; Babić, N; Grković, D; Jovanović, P; Miljković, A, )	0.6
"Both LT and TT are safe and effective for the treatment of OHT associated with uveitis and greater IOP reduction may be achieved by TT than by LT treatment."	( Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis. Kanda, T; Mine, I; Sakurai, Y; Shibata, M; Taguchi, M; Takeuchi, M, 2017)	0.69
" The most common treatment-related adverse events for the travoprost group were ocular hyperemia and eyelash growth."	( A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. Aljasim, LA; Bradfield, Y; Dixon, ER; Feldman, R; Gustafson, N; Landry, T; Salem, C; Venkataraman, S, 2017)	0.97
" Travoprost was well-tolerated, and no treatment-related systemic adverse events were reported."	( A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. Aljasim, LA; Bradfield, Y; Dixon, ER; Feldman, R; Gustafson, N; Landry, T; Salem, C; Venkataraman, S, 2017)	1.63
" A major challenge in the treatment is the occurrence of adverse events and poor adherence."	( The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells. Nagstrup, AH, 2023)	0.91

Excerpt	Relevance	Reference
"Subjects who qualified at screening began a run-in period dosing timolol twice daily for 3 weeks."	( Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Davis, AA; Landry, T; Orengo-Nania, S; Silver, LH; Von Tress, M; Weiner, A, 2001)	0.67
"We evaluated conjunctival hyperemia by a standard photographic measure at the slit lamp and by anterior segment photographs in healthy subjects after dosing for 5 days with latanoprost, bimatoprost, or travoprost."	( Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Jackson, AL; Kolker, AE; Leech, J; Stewart, JA; Stewart, WC, 2003)	0.72
" The dosing is once per day in the evening, and storage does not require refrigeration."	( Travoprost: a potent ocular hypotensive agent. Al-Jazzaf, AM; DeSantis, L; Netland, PA, 2003)	1.76
"A single centered, active-controlled, three-period crossover comparison that evaluated conjunctival and corneal punctate staining, by grade and individual stains, in healthy subjects after dosing for five days in one eye with latanoprost, bimatoprost, or travoprost."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.74
"33) or at 1 hour after dosing (latanoprost 23."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.56
" These agents are typically dosed once daily."	( Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Andrew, RM; Bergamini, MV; Darell Turner, F; Dubiner, HB; Landry, T; Przydryga, J; Robertson, S; Silver, LH; Sircy, MD; Weiner, A, 2004)	0.57
" The following 5 different dosing protocols were studied: latanoprost with bimatoprost added, bimatoprost with latanoprost added, latanoprost with travoprost added, travoprost with latanoprost added, and latanoprost with a second dose of latanoprost added."	( Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Gagliuso, DJ; Mittag, TW; Podos, SM; Wang, RF, 2004)	0.81
" This study demonstrates that the fixed combination of travoprost/timolol produces significant and clinically relevant reductions of IOP in a once-daily dosing regimen."	( Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Bergamini, MV; Henry, JC; Katz, GJ; Landry, TA; Lewis, RA; Mallick, S; Robertson, SM; Schuman, JS; Sullivan, EK; Wells, DT, 2005)	0.83
"After a 6-week medicine-free period, 33 patients were randomized to receive travoprost dosed in the morning or evening."	( 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Jenkins, JN; Kaltsos, K; Konstas, AG; Mikropoulos, D; Stewart, WC, 2006)	0.79
" At 10 am, the evening dosing provided a statistically lower IOP (17."	( 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Jenkins, JN; Kaltsos, K; Konstas, AG; Mikropoulos, D; Stewart, WC, 2006)	0.56
" However, the evening dosing of travoprost demonstrates slightly greater daytime efficacy, with a narrower range of 24-hour pressure."	( 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Jenkins, JN; Kaltsos, K; Konstas, AG; Mikropoulos, D; Stewart, WC, 2006)	0.84
"5% ophthalmic solution dosed in the morning and evening."	( A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Andrew, R; Denis, P; Friren, B; Wells, D, )	0.37
"5% ophthalmic solution, dosed in the morning or evening, controlled IOP consistently throughout the day."	( A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Andrew, R; Denis, P; Friren, B; Wells, D, )	0.37
"To evaluate the recently introduced Travatan Dosing Aid (TDA) for its accuracy in recording and dispensing eyedrops."	( Accuracy and performance of a commercially available Dosing Aid. Cronin, TH; Kahook, MY; Lathrop, KL; Noecker, RJ, 2007)	0.34
"005% (Xalatan) dosed once daily in patients with primary open-angle glaucoma or ocular hypertension."	( Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Castillo, A; Fernández-Vidal, A; García-Feijoo, J; García-Sánchez, J; Martínez-de-la-Casa, JM; Méndez, C, 2006)	0.61
" The TRAV group (n = 29) dosed once daily at 9:00 PM while the DTFC group (n = 27) dosed twice daily at 9:00 AM and 9:00 PM."	( Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Batista, WD; da Silva, LJ; Figueiredo, CR; Franklin, LM; Netto, JA; Suzuki, ER, 2006)	0.6
" A second group of animals was exposed to the medications through a dosing regimen of 1 drop/min (lpar3 drops total) (n=4/group)."	( Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Cavanagh, HD; Lakshman, N; Petroll, WM; Whitson, JT, )	0.13
"Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.61
"This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan Dosing Aid, Alcon Research Ltd."	( Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Bergamini, MV; Berke, SJ; Day, D; Flowers, B; Landry, TA; Mallick, S; Piltz-Seymour, J; Smoot, TM; Teague, J; Wand, M, 2006)	0.79
" In addition, each physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid."	( Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Bergamini, MV; Berke, SJ; Day, D; Flowers, B; Landry, TA; Mallick, S; Piltz-Seymour, J; Smoot, TM; Teague, J; Wand, M, 2006)	0.8
" Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid."	( Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Bergamini, MV; Berke, SJ; Day, D; Flowers, B; Landry, TA; Mallick, S; Piltz-Seymour, J; Smoot, TM; Teague, J; Wand, M, 2006)	0.59
"The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed."	( Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Bergamini, MV; Berke, SJ; Day, D; Flowers, B; Landry, TA; Mallick, S; Piltz-Seymour, J; Smoot, TM; Teague, J; Wand, M, 2006)	1.15
"004% without BAC (n=344) dosed once-daily each evening."	( Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. Bergamini, MV; Dickerson, JE; Hua, SY; James, JE; Katz, GJ; Landry, TA; Lewis, RA; Montgomery, DB; Sullivan, EK; Weiss, MJ; Wells, DT, 2007)	1.78
"To assess the accuracy of Travatan Dosing Aid recordings."	( The TRAVATAN Dosing Aid accurately records when drops are taken. Congdon, NG; Friedman, DS; Jampel, HD; Miller, R; Quigley, HA, 2007)	0.34
"Physicians and patients used the Dosing Aid, and logs of usage were compared to the data obtained from the Dosing Aid."	( The TRAVATAN Dosing Aid accurately records when drops are taken. Congdon, NG; Friedman, DS; Jampel, HD; Miller, R; Quigley, HA, 2007)	0.34
"The Dosing Aid accurately recorded most eyedrops administered by patients and physicians."	( The TRAVATAN Dosing Aid accurately records when drops are taken. Congdon, NG; Friedman, DS; Jampel, HD; Miller, R; Quigley, HA, 2007)	0.34
"5% ophthalmic solution (Lat/Tim), dosed once daily in the morning, in patients with open-angle glaucoma (OAG) or ocular hypertension (OH)."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.37
" Conjunctival hyperaemia was evaluated clinically at 12, 24, 36 and 72 hours after dosing and volunteers reported all ocular adverse effects."	( Conjunctival hyperaemia and other ocular adverse effects on healthy African subjects after single dosing with 0.004% Travoprost. Adedapo, AD; Adeoti, CO; Ashaye, AO; Olusanya, BA, 2007)	0.55
"Once-daily dosing of travoprost with sofZia produced significantly fewer corneal changes and less conjunctival inflammation than latanoprost preserved with BAK."	( Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Kahook, MY; Noecker, RJ, 2008)	0.9
" Patient dosing preference (a."	( Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Battista, RA; Haidich, AB; Konstas, AG; Yan, DB, 2008)	0.58
"The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean ± standard deviation: 17."	( Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Battista, RA; Haidich, AB; Konstas, AG; Yan, DB, 2008)	0.58
"To evaluate the 24 h efficacy and safety of the travoprost/timolol maleate fixed combination (TTFC) versus travoprost when both are dosed in the evening in primary open-angle glaucoma patients."	( Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Haidich, AB; Konstas, AG; Mikropoulos, D; Ntampos, KS; Stewart, WC, 2009)	0.86
"This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients."	( Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Haidich, AB; Konstas, AG; Mikropoulos, D; Ntampos, KS; Stewart, WC, 2009)	0.8
" All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed."	( Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Friedman, DS; Jampel, HD; Jiang, Y; Okeke, CO; Plyler, RJ; Quigley, HA; Ying, GS, 2009)	0.58
" Patients were then treated with the opposite dosing regimen for 8 weeks and IOP measurements were repeated."	( Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Konstas, AG; Nasr, MB; Nelson, LA; Stewart, JA; Stewart, WC; Tsironi, S; Vakalis, AN, 2009)	0.61
"Both morning and evening administration of TTFC provide effective 24-hour IOP reduction, but evening dosing demonstrates better 24-hour pressure control."	( Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Konstas, AG; Nasr, MB; Nelson, LA; Stewart, JA; Stewart, WC; Tsironi, S; Vakalis, AN, 2009)	0.61
"Adherence was measured with the Travalert Dosing Aid on 58 consecutive, regularly followed-up glaucoma patients already on self-administered travoprost."	( Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma. Géczy, A; Holló, G; Kóthy, P; Vargha, P, )	0.33
" All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc."	( Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Friedman, DS; Jampel, HD; Jiang, Y; Okeke, CO; Plyler, RJ; Quigley, HA; Ying, GS, 2009)	0.35
"In an observational study, participants who took 75% or fewer doses (as measured using the travoprost Dosing Aid [DA]) during an initial 3-month period were randomized into 2 groups."	( Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Friedman, DS; Jampel, HD; Jiang, Y; Okeke, CO; Plyler, RJ; Quigley, HA; Ying, GS, 2009)	0.57
" Multiple daily dosing with the drug produced a persistent IOP-lowering effect."	( Evaluation of monkey intraocular pressure by rebound tonometer. Cao, G; Chen, L; Li, N; Liu, X; Ma, J; Pang, IH; Qiu, J; Yan, N; Yu, M; Yu, W, 2009)	0.35
"To assess adherence in glaucoma patients using the Travatan Dosing Aid (TDA); to record differences in adherence by age, sex, therapy, systemic therapies, years from diagnosis, type of therapy and intraocular pressure (IOP)."	( Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Bianchi, PE; Milano, G; Pasinetti, GM; Rossi, GC; Scudeller, L; Tinelli, C, 2010)	0.57
"To identify patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data."	( Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid. Ajit, RR; Fenerty, CH; Henson, DB, 2010)	0.62
" In total 23 of the complete data sets showed good adherence (dosing within +/-4 h of the agreed dosing time on >80% of occasions), 3 patients discontinued usage before 75 days, 4 showed frequent drug holidays (no dosing for > or =8 days) and 7 frequently missed doses with adherence rates of <60%."	( Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid. Ajit, RR; Fenerty, CH; Henson, DB, 2010)	0.36
"After up to a 6-week medicine-free period, XFG patients were randomized to either TTFC or LTFC for 3 months, dosed each evening, and then changed to the opposite treatment for another 3 months."	( 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Dimopoulos, AT; Embeslidis, TA; Haidich, AB; Konstas, AG; Mikropoulos, DG; Papanastasiou, A; Stewart, WC, 2010)	0.61
"5%), in order to evaluate both efficacy (intraocular pressure lowering) and tolerability (patient and investigator satisfaction) of two dosing regimens--evening (PM) and morning (AM)."	( Comparison of evening and morning dosing of travoprost 0.004%/timolol 0.5% fixed combination in 6 month period. Bojić, L; Dosen, VM; Ekert, M; Laus, KN; Mandić, Z; Suić, SP, 2010)	0.62
"To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA)."	( Do adherence rates and glaucomatous visual field progression correlate? Bianchi, PE; Pasinetti, GM; Radaelli, R; Rossi, GC; Scudeller, L, )	0.13
" The potential benefit to the human ocular surface with oncedaily dosing needs to be evaluated clinically."	( Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Baudouin, C; Brignole-Baudouin, F; Liang, H; Pauly, A; Riancho, L, 2011)	0.7
"In this prospective randomized controlled trial, subjects with IOP of at least 22 mm Hg in one or both eyes at 0900 h, and IOP of at least 21 mm Hg in one or both eyes at 1100 h and 1600 h at two eligibility visits were randomly assigned to receive either TRA/TIM BAK-free (n=195) or TRA/TIM (n=193), dosed once daily in the morning (0900 h) for 6 weeks."	( Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Bae, K; Iwamoto, Y; Kitazawa, Y; Kotake, S; Sasaki, N; Smith, P, 2011)	1.81
" A change was done from prior monotherapy at day 0 to TTFC dosed once a day, regardless in the evening or in the morning, without washout period."	( Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period. Barisić, F; Biuk, D; Bojić, L; Clementi, D; Dobutović, D; Dogan, KK; Dosen, VM; Ekert, M; Geser, MZ; Iveković, R; Jurić-Miletić, A; Kovacević, S; Kovacić, Z; Krolo, I; Mandić, Z; Novak-Laus, K; Pavan, J; Pelcić, G; Popović-Suić, S; Susić, N; Tomić, M, 2010)	0.6
" All subjects were given a Travalert(®) dosing aid and were reviewed after one and four months."	( [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients]. Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011)	0.37
"Compliance is very important in the treatment of glaucoma, and our study provides objective data through the use of Travalert dosing aid with relative compliances of 70%."	( [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients]. Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011)	0.37
"UBM revealed cyclodialysis in the patient's affected eye after a single dosage of bimatoprost."	( A case hypersensitive to bimatoprost and dexamethasone. Li, X; Liu, G; Liu, X; Wang, Y; Xiang, H; Yu, W, 2011)	0.37
" They were then crossed over to the opposite dosing schedule for the following month."	( Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. Carlsson, A; Crichton, AC; Ford, BA; Gooi, M, 2013)	0.39
"Adherence was compared between morning versus evening dosing and first versus second month dosing."	( Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. Carlsson, A; Crichton, AC; Ford, BA; Gooi, M, 2013)	0.39
"07) in adherence between morning dosing (90."	( Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. Carlsson, A; Crichton, AC; Ford, BA; Gooi, M, 2013)	0.39
"A total of 371 patients randomly received travoprost BAK-free (n=185) or travoprost BAK (n=186) dosed once daily in the evening for 3 months."	( Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Coote, M; Denis, P; Gandolfi, S; Goldberg, I; Paredes, T; Pillai, MR; Stalmans, I; Volksone, L; Wells, A, )	0.74
"To study the effect of patient education and the TravAlert(®) -Eyot(®) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert(®) dosing aid."	( Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Beckers, HJ; Brink, HM; Busch, MJ; Colen, TP; Schouten, JS; Webers, CA, 2013)	0.39
" Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education."	( Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Beckers, HJ; Brink, HM; Busch, MJ; Colen, TP; Schouten, JS; Webers, CA, 2013)	0.39
" An 8-month follow-up period, using an electronic adherence monitoring device (Travalert dosing aid, TDA), will indicate if the intervention is likely to be sustained in the longer term."	( Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management. Bhattacharya, D; Broadway, DC; Cate, H; Clark, A; Fordham, R; Notley, C, 2012)	0.38
"A predictive model for nonadherence was developed from the Travatan Dosing Aid (TDA) study (n = 196) using stepwise logistic regression."	( Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Boland, MV; Chang, DS; Frazier, T; Friedman, DS; Plyler, R, 2013)	0.39
" Adherence was calculated as the percentage of days on which a dose was taken within 4 hours of the average dosing time for that patient."	( Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Boland, MV; Chang, DS; Frazier, T; Friedman, DS; Plyler, R, 2013)	0.39
" Participants were randomised into two groups and adherence was measured over 8 months, using an electronic monitoring device (Travalert® dosing aid, TDA)."	( Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). Bhattacharya, D; Broadway, DC; Cate, H; Clark, A; Fordham, R; Holland, R, 2014)	0.4
"5% (TRAV+TIM; unfixed) using electronic dosing aids."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.71
"TTFC was administered once daily in the morning or evening with a single dosing aid."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.71
"Adherence with administered medication, as recorded by the dosing aids."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.71

Role	Description
antiglaucoma drug	Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
ophthalmology drug	Any compound used for the treatment of eye conditions or eye diseases.
prostaglandin receptor agonist	An agonist that binds to and activates prostaglandin receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
prostaglandins Falpha
(trifluoromethyl)benzenes	An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
isopropyl ester	Any carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	74.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	43.9000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID485979	Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	213 (48.52)	29.6817
2010's	194 (44.19)	24.3611
2020's	32 (7.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	166 (34.16%)	5.53%
Reviews	48 (9.88%)	6.00%
Case Studies	39 (8.02%)	4.05%
Observational	9 (1.85%)	0.25%
Other	224 (46.09%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (134)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects With Open-angle Glaucoma or Ocular Hypertension [NCT06152861]	Phase 2	250 participants (Anticipated)	Interventional	2023-11-15	Recruiting
A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma [NCT00762645]	Phase 4	30 participants (Actual)	Interventional	2007-02-28	Completed
Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® [NCT00798759]	Phase 4	236 participants (Actual)	Interventional	2008-12-31	Completed
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma [NCT01361841]		141 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension [NCT02796560]	Phase 4	76 participants (Actual)	Interventional	2016-07-01	Completed
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan® [NCT00708422]	Phase 4	231 participants (Actual)	Interventional	2008-07-31	Completed
A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00760539]	Phase 3	87 participants (Actual)	Interventional	2008-06-30	Completed
Comparison Between the Effect of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on Diurnal Intraocular Pressure Fluctuation in Patients Having Primary Open-angle Glaucoma [NCT04461249]		60 participants (Actual)	Observational	2019-06-01	Completed
A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally [NCT01312454]	Phase 2	4 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Management decision)
Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%) [NCT01336569]	Phase 4	50 participants (Actual)	Interventional	2011-02-28	Completed
A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00928590]	Phase 3	155 participants (Actual)	Interventional	2009-07-31	Completed
Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) [NCT01230736]	Phase 4	105 participants (Actual)	Interventional	2010-10-31	Completed
A Phase 2, Randomized Study Evaluating the Safety and Efficacy of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® in Subjects With Glaucoma or Ocular Hypertension and Ocular Surface Disease [NCT01254370]	Phase 2	105 participants (Actual)	Interventional	2010-11-30	Completed
[NCT00892762]	Phase 3	434 participants (Actual)	Interventional	2009-06-30	Completed
1-year Randomized Control Trial Investigating the Value of an Intervention to Enhance Adherence in Glaucoma Patients Receiving Prostaglandin Monotherapy and in Patients Who Are Candidates for Adjunctive Therapy [NCT00756184]	Phase 4	107 participants (Actual)	Interventional	2007-09-30	Completed
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy [NCT01263444]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant [NCT04615403]	Phase 2	33 participants (Actual)	Interventional	2020-11-19	Completed
Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% [NCT03868124]	Phase 3	560 participants (Actual)	Interventional	2018-09-17	Active, not recruiting
Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP 0.5% [NCT02754596]	Phase 2	154 participants (Actual)	Interventional	2016-03-29	Completed
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation [NCT00705757]	Phase 4	89 participants (Actual)	Interventional	2008-03-31	Completed
A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) [NCT05335122]	Phase 2	105 participants (Anticipated)	Interventional	2022-03-16	Active, not recruiting
A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure [NCT01474135]	Phase 2	93 participants (Actual)	Interventional	2011-12-31	Completed
A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00672997]	Phase 3	301 participants (Actual)	Interventional	2008-05-31	Completed
Comparison of Safety and IOP-Lowering Efficacy of Three Alternative Travoprost Formulations to Vehicle and TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00670033]	Phase 2	158 participants (Actual)	Interventional	2008-04-30	Completed
A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation [NCT02105311]	Phase 4	60 participants (Actual)	Interventional	2014-03-31	Completed
Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes [NCT02136589]	Phase 4	40 participants (Actual)	Interventional	2008-09-30	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma [NCT00981786]	Phase 4	51 participants (Actual)	Interventional	2009-08-31	Completed
[NCT00759239]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Completed
Comparison of Selective Laser Trabeculoplasty With Prostaglandin Analogues for Lowering Intraocular Pressure in Eyes With Primary Angle Closure Glaucoma [NCT01004900]	Phase 3	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
Dry Eye and Irritation Comparison of Latanoprost 0.005% With the Preservative Benzalkonium Chloride (BAC) Vs Travoprost 0.004% Without BAC [NCT00803387]		33 participants (Actual)	Observational	2008-04-30	Completed
A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study) [NCT00887029]	Phase 4	54 participants (Actual)	Interventional	2009-01-31	Completed
Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma: A Randomised Controlled Trial [NCT00980473]	Phase 3	80 participants (Anticipated)	Interventional	2007-09-30	Recruiting
[NCT00872651]	Phase 3	242 participants (Actual)	Interventional	2010-01-31	Completed
A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma [NCT00758342]	Phase 4	37 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to difficulty of enrolling patients)
An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution [NCT00761319]	Phase 3	705 participants (Actual)	Interventional	2008-10-31	Completed
A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening [NCT00676637]		55 participants (Actual)	Observational	2008-05-31	Completed
[NCT00767494]	Phase 3	17 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Project Cancelled)
Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients [NCT00308945]	Phase 4	20 participants (Actual)	Interventional	2003-11-30	Completed
[NCT00767481]	Phase 3	6 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Project Cancelled)
[NCT00440011]	Phase 4	266 participants (Actual)	Interventional	2006-08-31	Completed
A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening [NCT00680329]		55 participants (Actual)	Observational	2008-05-31	Completed
A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components [NCT01789736]	Phase 2	234 participants (Actual)	Interventional	2013-02-28	Completed
Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®, on the Ocular Surface of Clinically Healthy Subjects. [NCT03965052]	Phase 1	24 participants (Actual)	Interventional	2019-04-24	Completed
An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution [NCT00690794]	Phase 3	726 participants (Actual)	Interventional	2008-07-31	Completed
A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00848536]	Phase 3	371 participants (Actual)	Interventional	2009-03-31	Completed
Ocular Surface Changes With Topical Prostaglandin Analog Therapy [NCT00798694]	Phase 4	58 participants (Actual)	Interventional	2008-11-30	Completed
An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® [NCT00799682]	Phase 4	56 participants (Actual)	Interventional	2008-10-31	Completed
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma [NCT01978015]	Phase 4	69 participants (Actual)	Interventional	2011-10-31	Completed
Safety And Efficacy Of Topical Prostaglandin F2α Analogs In Combination With Fractional CO2 Laser And 308 Excimer Light In Treatment Of Vitiligo [NCT04577027]	Phase 4	30 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) [NCT01327599]	Phase 4	60 participants (Actual)	Interventional	2011-08-31	Completed
The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients [NCT00966940]	Phase 4	51 participants (Actual)	Interventional	2009-09-30	Completed
A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Mon [NCT00121147]		200 participants	Interventional	2003-09-30	Completed
[NCT00333125]	Phase 3	319 participants (Actual)	Interventional	2006-04-30	Completed
A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan). [NCT00847483]	Phase 4	375 participants (Actual)	Interventional	2002-01-31	Completed
A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension [NCT00061503]	Phase 4	0 participants	Interventional	2003-04-30	Completed
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00527501]	Phase 2	136 participants (Actual)	Interventional	2007-08-31	Completed
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution [NCT01485822]		88 participants (Actual)	Observational	2004-07-31	Terminated(stopped due to Study objectives met)
Evaluation of Continuous IOP Measurement and the Influence of Drug Induced IOP Decrease on the Measurement [NCT01491867]		9 participants (Actual)	Interventional	2011-12-31	Completed
Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension [NCT00348023]	Phase 4	0 participants	Interventional		Completed
Trabeculectomy Versus 2-iStent and Prostaglandin Study [NCT03274323]		0 participants (Actual)	Interventional	2018-01-12	Withdrawn(stopped due to Difficulty obtaining IDE by the FDA. Currently not worthwhile to pursue further.)
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy [NCT00444665]	Phase 4	750 participants (Anticipated)	Interventional	2007-05-31	Completed
In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study [NCT01315574]	Phase 4	14 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Slow Enrollment)
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00311389]	Phase 3	408 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00293761]	Phase 3	109 participants (Actual)	Interventional	2006-01-31	Completed
[NCT00293800]	Phase 3	173 participants (Actual)	Interventional	2004-07-31	Completed
An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures [NCT00329095]	Phase 4	60 participants	Interventional	2005-12-31	Completed
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination [NCT00331240]	Phase 3	32 participants	Interventional	2006-03-31	Completed
Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial [NCT00435058]		54 participants	Interventional	2005-09-30	Completed
Effects of Travoprost on Neovascular Glaucoma [NCT00441181]		40 participants (Anticipated)	Interventional	2008-01-31	Withdrawn
A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma [NCT00444184]	Phase 4	32 participants (Actual)	Interventional	2007-03-31	Completed
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers [NCT00468988]	Phase 4	30 participants (Anticipated)	Interventional	2007-05-31	Completed
[NCT00539526]	Phase 4	106 participants (Actual)	Interventional	2007-09-30	Completed
[NCT00527592]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
[NCT01114893]	Phase 2	60 participants (Actual)	Interventional	2010-04-30	Completed
[NCT00716742]		1,099 participants (Actual)	Observational	2004-09-30	Completed
A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma [NCT02371746]	Phase 2	41 participants (Actual)	Interventional	2015-01-01	Completed
Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany [NCT00519753]	Phase 4	522 participants (Actual)	Interventional	2007-08-31	Completed
Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination [NCT01514721]	Phase 4	37 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to low enrollment)
Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves [NCT01535768]	Phase 4	150 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study [NCT01542710]		80 participants (Actual)	Interventional	2011-01-31	Completed
A Five-Year, Multicenter, Commercial Label Safety Study of TRAVATAN® 0.004% in Patients With TRAVATAN-Induced Iris Pigmentation Changes [NCT00047554]		336 participants (Actual)	Observational	2003-05-31	Terminated(stopped due to Study objectives met)
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00051142]	Phase 3	0 participants	Interventional	2001-02-28	Completed
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma. [NCT00051181]	Phase 3	0 participants	Interventional	2000-01-31	Completed
A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT02914509]	Phase 3	565 participants (Actual)	Interventional	2016-11-07	Completed
A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension. [NCT00051155]	Phase 3	0 participants	Interventional	2001-01-31	Completed
Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% [NCT03519386]	Phase 3	590 participants (Actual)	Interventional	2018-07-26	Active, not recruiting
Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5% [NCT00508469]	Phase 4	102 participants (Actual)	Interventional	2007-10-31	Completed
A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00763061]	Phase 4	111 participants (Actual)	Interventional	2006-05-31	Completed
[NCT00288951]	Phase 3	690 participants (Actual)	Interventional	2004-10-31	Completed
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00293787]	Phase 3	156 participants (Actual)	Interventional	2004-06-30	Completed
Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004% [NCT00347802]	Phase 4	0 participants	Interventional		Completed
Post Marketing Surveillance Study to Evaluate the Safety Profile of Travacom (Travoprost/Timolol Fixed Combination) in Patients With Open-Angle Glaucoma or Ocular Hypertension Across India [NCT01510132]	Phase 4	0 participants (Actual)	Interventional	2012-01-31	Withdrawn
The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. [NCT01655758]	Phase 4	61 participants (Actual)	Interventional	2002-01-31	Completed
Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension [NCT00471068]	Phase 4	46 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Question raised by Ethics Committee)
Assessing the Efficacy of DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as a Replacement Therapy in Glaucoma Patients in Russia, Previously on Prior Prostaglandin Analogue or Beta-blocker Monotherapy [NCT01696383]	Phase 4	0 participants (Actual)	Interventional	2013-02-28	Withdrawn(stopped due to Management decision)
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost [NCT01937299]	Phase 4	307 participants (Actual)	Interventional	2013-10-31	Completed
24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy [NCT01779284]	Phase 4	42 participants (Actual)	Interventional	2012-01-31	Completed
Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid [NCT00465803]	Phase 3	81 participants (Actual)	Interventional	2007-03-31	Completed
Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy [NCT01493427]	Phase 4	202 participants (Actual)	Interventional	2011-12-31	Completed
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients [NCT01652664]	Phase 3	184 participants (Actual)	Interventional	2012-09-30	Completed
[NCT01547598]	Phase 4	135 participants (Actual)	Interventional	2011-12-31	Completed
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients [NCT01658839]	Phase 1	25 participants (Actual)	Interventional	2013-01-31	Completed
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma [NCT01711177]		14 participants (Actual)	Interventional	2012-10-31	Completed
A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution [NCT01443988]	Phase 4	101 participants (Actual)	Interventional	2011-09-30	Completed
Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery [NCT06061718]	Phase 3	60 participants (Anticipated)	Interventional	2023-09-11	Recruiting
Safety and IOP Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions Dosed BID Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00637130]	Phase 2	138 participants (Actual)	Interventional	2007-10-31	Completed
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. [NCT01927406]	Phase 4	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Funding source unavailable)
[NCT01298687]	Phase 2	67 participants (Actual)	Interventional	2011-02-28	Completed
A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With No [NCT03150160]	Phase 4	1 participants (Actual)	Interventional	2017-09-21	Completed
A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic S [NCT01444040]	Phase 4	196 participants (Actual)	Interventional	2011-09-30	Completed
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hy [NCT06066645]	Phase 3	150 participants (Anticipated)	Interventional	2023-09-14	Recruiting
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle [NCT01664039]	Phase 4	104 participants (Actual)	Interventional	2012-09-30	Completed
A Long-term Safety Study of Once-daily TRAVATAN [NCT00051168]	Phase 3	502 participants (Actual)	Interventional	2006-01-31	Completed
[NCT01253902]	Phase 4	164 participants (Actual)	Interventional	2010-12-31	Completed
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting [NCT04828057]		50 participants (Actual)	Observational	2021-09-01	Completed
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension [NCT00372827]	Phase 4	245 participants	Interventional	2004-02-29	Completed
Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy [NCT01510145]	Phase 4	191 participants (Actual)	Interventional	2012-02-29	Completed
A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01453855]	Phase 3	1,099 participants (Actual)	Interventional	2011-11-30	Completed
The Effects of Topical Beta Blocker and Prostaglandin on Interval Intraocular Pressure in Intravitreal Injection - a Randomised Controlled Prospective Study [NCT04868175]		64 participants (Actual)	Interventional	2019-10-01	Completed
A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT02140060]	Phase 2	327 participants (Actual)	Interventional	2014-06-30	Completed
Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma [NCT01995136]	Phase 4	32 participants (Actual)	Interventional	2013-09-30	Completed
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension [NCT00471380]	Phase 4	46 participants (Actual)	Interventional	2007-03-31	Completed
A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin [NCT02873806]	Phase 4	53 participants (Actual)	Interventional	2013-03-31	Completed
[NCT01881126]	Phase 4	93 participants (Actual)	Interventional	2013-06-30	Completed
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue [NCT01937312]	Phase 4	282 participants (Actual)	Interventional	2013-10-31	Completed
Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) [NCT01464424]	Phase 4	84 participants (Actual)	Interventional	2011-10-31	Completed
A 90-Day, Open-Label, Multi-Site, Pilot Study Evaluating the Safety and Intraocular Lowering Effect of Delivering Travoprost Using a Punctal Plug Delivery System (Evolute®) in Subjects With Elevated Intraocular Pressure [NCT04962009]		12 participants (Actual)	Interventional	2021-09-08	Completed
Three Month Safety and Efficacy Study of TRAVATAN® vs Travoprost Ophthalmic Solution, 0.004% [NCT01452009]	Phase 3	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to Management Decision)
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue [NCT02419508]	Phase 4	290 participants (Actual)	Interventional	2015-08-07	Completed
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) [NCT02730871]	Phase 4	173 participants (Actual)	Interventional	2016-06-24	Terminated(stopped due to Enrollment Challenges)
[NCT02097719]	Phase 4	100 participants (Actual)	Interventional	2014-05-31	Completed
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker [NCT02003391]	Phase 4	157 participants (Actual)	Interventional	2013-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00051168 (1) [back to overview]	Mean Intraocular Pressure
NCT00440011 (2) [back to overview]	Tolerability - Conjunctival Hyperemia
NCT00440011 (2) [back to overview]	Intraocular Pressure (IOP)
NCT00471068 (1) [back to overview]	Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment
NCT00471380 (1) [back to overview]	Intra Ocular Pressure (IOP)
NCT00508469 (1) [back to overview]	Adherence
NCT00527592 (1) [back to overview]	Comfort Immediately After Dosing
NCT00539526 (3) [back to overview]	Change From Baseline in Tear Break-Up Time (TBUT) at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Corneal Staining With Fluorescein at Month 3
NCT00690794 (2) [back to overview]	Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00690794 (2) [back to overview]	Percentage of Patients With Corneal Fluorescein Staining Score = 0
NCT00705757 (1) [back to overview]	The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.
NCT00708422 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00708422 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)
NCT00716742 (1) [back to overview]	Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
NCT00758342 (1) [back to overview]	Mean IOP (Intraocular Pressure)
NCT00761319 (2) [back to overview]	Percentage of Patients With Corneal Fluorescein Staining Score = 0
NCT00761319 (2) [back to overview]	Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00762645 (2) [back to overview]	Number of Patients With Peripheral Anterior Synechiae (PAS)
NCT00762645 (2) [back to overview]	Mean Intraocular Pressure (IOP)
NCT00763061 (4) [back to overview]	Mean IOP Change From Baseline at 9 AM
NCT00763061 (4) [back to overview]	Mean IOP Change at 4 PM
NCT00763061 (4) [back to overview]	Week 12 - Mean IOP At 4 PM
NCT00763061 (4) [back to overview]	Mean Intraocular Pressure (IOP) at 9 AM
NCT00798694 (6) [back to overview]	Ocular Surface Disease Index Score
NCT00798694 (6) [back to overview]	Intraocular Pressure
NCT00798694 (6) [back to overview]	Corneal Staining Score
NCT00798694 (6) [back to overview]	Conjunctival Hyperemia Score
NCT00798694 (6) [back to overview]	Change in Tear Break up Time (TBUT)
NCT00798694 (6) [back to overview]	Tear Production
NCT00798759 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)
NCT00798759 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00848536 (3) [back to overview]	Mean Intraocular Pressure at 4:00 pm
NCT00848536 (3) [back to overview]	Mean Intraocular Pressure at 9:00 am
NCT00848536 (3) [back to overview]	Mean Intraocular Pressure at 11:00 am
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 10:00 AM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 12:00 PM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 2:00 PM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 4:00 PM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 6:00 PM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 8:00 PM
NCT00966940 (7) [back to overview]	Mean Intraocular Pressure (IOP) at 8:00 AM
NCT01114893 (2) [back to overview]	IOP Change From Baseline at 8 PM on Day 5
NCT01114893 (2) [back to overview]	Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5
NCT01253902 (3) [back to overview]	Mean Conjunctival Hyperemia at Week 12
NCT01253902 (3) [back to overview]	Mean Corneal Staining With Fluorescein at Week 12
NCT01253902 (3) [back to overview]	Mean Tear Break Up Time (TBUT) at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12
NCT01263444 (4) [back to overview]	Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP at Week 4
NCT01263444 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12
NCT01315574 (3) [back to overview]	Corneal Fluorescein Staining Score
NCT01315574 (3) [back to overview]	Effectiveness in Lowering Intraocular Pressure
NCT01315574 (3) [back to overview]	Tear Film Break-Up Time
NCT01327599 (5) [back to overview]	Mean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in IOP at Week 4 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Week 12 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Percentage of Subjects Who Reach Target IOP of ≤ 18 mmHg in Subjects Using Ganfort® at Baseline
NCT01336569 (1) [back to overview]	Mean Intraocular Pressure (IOP) Change at the Final Visit From Baseline (Prior Beta-blocker Monotherapy)
NCT01453855 (1) [back to overview]	Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)
NCT01464424 (2) [back to overview]	Overall Mean Intraocular Pressure (IOP)
NCT01464424 (2) [back to overview]	Mean IOP at Each After Office Hour Evaluation Timepoint
NCT01493427 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)
NCT01493427 (2) [back to overview]	Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks
NCT01510145 (2) [back to overview]	Percentage of Subjects Who Reach Target IOP (≤18 mmHg)
NCT01510145 (2) [back to overview]	Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)
NCT01547598 (5) [back to overview]	Mean Diurnal Intraocular Pressure (IOP)
NCT01547598 (5) [back to overview]	Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 12
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 6
NCT01547598 (5) [back to overview]	Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg
NCT01652664 (1) [back to overview]	Mean Change From Baseline in IOP at Month 3
NCT01658839 (6) [back to overview]	Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax)
NCT01658839 (6) [back to overview]	Time to Last Measurable Concentration (Tlast)
NCT01658839 (6) [back to overview]	Time to Reach Cmax (Tmax)
NCT01658839 (6) [back to overview]	Area Under the Analyte Plasma Concentration-time Curve to the Last Quantifiable Sampling Time Point [AUC(0-tlast)]
NCT01658839 (6) [back to overview]	Area Under the Analyte Plasma Concentration-time Curve Over the Dosing Interval (Inf)[AUC(0-∞)]
NCT01658839 (6) [back to overview]	Half-life (t½)
NCT01664039 (8) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6
NCT01664039 (8) [back to overview]	Mean Change From Baseline in IOP at Week 6 and Month 3
NCT01664039 (8) [back to overview]	Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit
NCT01664039 (8) [back to overview]	Percentage of Subjects Who Reached Target IOP at Each Visit
NCT01711177 (1) [back to overview]	Blood Oxygenation
NCT01881126 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT01937299 (3) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean IOP at Week 6 for Each Time Point (8 AM, 10 AM, 3 PM, 5 PM)
NCT01937312 (4) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01995136 (1) [back to overview]	Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12
NCT02003391 (3) [back to overview]	Mean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
NCT02003391 (3) [back to overview]	Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye
NCT02003391 (3) [back to overview]	Percentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
NCT02097719 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT02140060 (1) [back to overview]	Mean IOP at Week 6
NCT02371746 (1) [back to overview]	Summary of Change From Baseline Average Intraocular Pressure Diurnal Measurement by Treatment Group Population (Cohort 1)
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in Diurnal Intraocular Pressure (IOP) (Mean of Changes at 09:00 and 11:00 Time Points) at Week 6
NCT02730871 (5) [back to overview]	Mean Diurnal IOP at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02754596 (2) [back to overview]	IOP (mmHg) Change From Baseline at Week 12
NCT02754596 (2) [back to overview]	Severe Adverse Events
NCT02796560 (2) [back to overview]	Comfort and Intolerance to the Drops Questionnaire
NCT02796560 (2) [back to overview]	Intraocular Pressure
NCT02914509 (4) [back to overview]	Number of Participants With Serious Adverse Events
NCT02914509 (4) [back to overview]	Mean IOP
NCT02914509 (4) [back to overview]	Mean IOP
NCT02914509 (4) [back to overview]	Mean IOP
NCT03519386 (1) [back to overview]	Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative
NCT03868124 (1) [back to overview]	Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative
NCT03965052 (7) [back to overview]	Eye Comfort Index
NCT03965052 (7) [back to overview]	Number of Eyes of Chemosis
NCT03965052 (7) [back to overview]	Number of Participants With Adverse Events
NCT03965052 (7) [back to overview]	Visual Ability
NCT03965052 (7) [back to overview]	Changes in Intraocular Pressure
NCT03965052 (7) [back to overview]	Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade
NCT03965052 (7) [back to overview]	Number of Eyes With Epithelial Defects by Grade
NCT04615403 (1) [back to overview]	Ocular Safety
NCT04962009 (1) [back to overview]	Mean Percent Intraocular Pressure (IOP) Change

Mean Intraocular Pressure

"Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken.~All IOP measurements were performed with a Goldmann applanation tonometer." (NCT00051168)
Timeframe: At 5 years.

Intervention	millimeters mercury (mm Hg) (Mean)
Travatan	16.5

Intervention	mm Hg (millimeters mercury)*week (Mean)
	Week 8	Week 16	Week 24
Crossover Group ABB	179.20	188.82	201.50
Crossover Group BAA	191.89	196.26	191.93

Intervention	percentage of adherent patients (Number)
Travalert With Travoprost/Timolol Fixed Combination	63
Travalert With Travoprost and Timolol	43

Intervention	Seconds (Mean)
	Baseline	Month 3
Bimatoprost 0.03%	9.1	0.5
Latanoprost 0.005%	8.6	0.4
Travoprost 0.004%	7.9	1.7

Intervention	Lab* (Mean)
	Upper Lid	Lower Lid	Cheek/Face
Lumigan	-0.90	-0.37	0.30
Travatan	-0.90	0.17	0.51
Xalatan	-1.42	0.48	0.55

Intervention	Millimeters of mercury (mmHg) (Mean)
	Baseline	Change from Baseline at 1 Year
Lumigan®	20.8	-4.8
Travatan®	20.3	-4.3
Xalatan®	20.6	-4.3

Intervention	mm Hg (millimeters mercury) (Mean)
	9 AM measurement	4 PM measurement
Travoprost 0.004% + Brinzolamide 1.0%	17.58	17.11
Travoprost 0.004% + Tears Natural	20.59	18.50

Intervention	scores on a scale (Mean)
	Baseline	1 month	2 months
Group 1 Travatan Z	11.7	11.7	11.8
Group 1 Xalatan	10.8	10.8	11.1
Group 2 Travatan Z	14.2	8.1	11.2
Group 2 Xalatan	9.8	7.0	6.6

Intervention	seconds (Mean)
	1 month	2 months
Currently on Xalatan	-0.59	0.27
New to Meds	-0.86	-2.00

Intervention	mm Hg (Mean)
Travatan 0.004% QD	-3.9
Travoprost Vehicle	-0.9
Travoprost Group A	-2.7
Travoprost Group B	-5.7
Travoprost Group C	-4.8

Intervention	mm Hg (Mean)
Travatan 0.004% QD	-9.8
Travoprost Vehicle	-2.9
Travoprost Group A	-5.0
Travoprost Group B	-6.5
Travoprost Group C	-6.8

Intervention	Score on a scale (Mean)
Bimatoprost Ophthalmic Solution 0.01%	0.42
Travoprost Ophthalmic Solution 0.004%	0.46
Latanoprost Ophthalmic Solution 0.005%	0.44

Intervention	Score on a scale (Mean)
Bimatoprost Ophthalmic Solution 0.01%	0.31
Travoprost Ophthalmic Solution 0.004%	0.32
Latanoprost Ophthalmic Solution 0.005%	0.22

Intervention	mmHg (Mean)
	AZARGA + Latanoprost (n=22)	AZARGA + Travoprost (n=15)
Azarga	-7.1	-5.1

Intervention	millimeters mercury (mmHg) (Mean)
	Baseline (Day 1)	Change from baseline at Week 12
DUOTRAV®	20.0	-3.8

Intervention	millimeters mercury (mmHg) (Mean)
	Baseline (Day 1)	Change from Baseline at Week 4
DUOTRAV®	20.1	-3.8

Intervention	millimeters mercury (mmHg) (Least Squares Mean)
	Week 2 at 8 AM	Week 2 at 10 AM	Week 2 at 4 PM	Week 6 at 8 AM	Week 6 at 10 AM	Week 6 at 4 PM	Month 3 at 8 AM	Month 3 at 10 AM	Month 3 at 4 PM
TRAVATAN	19.5	18.6	18.3	19.3	18.6	18.1	19.3	18.6	18.0
Travoprost 0.003%	19.4	18.6	18.0	19.3	18.5	18.0	19.2	18.3	18.0

Intervention	millimeters mercury (mmHg) (Mean)
	4 pm (20 hours post dose)	6 pm (22 hours post dose)	8 pm (24 hours post dose)
LUMIGAN	17.08	17.32	17.26
TRAVATAN	17.74	17.52	17.06

Intervention	millimeters mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 12 (n=178)
TRAVATAN® BAK-free	17.0	-1.16

Intervention	mmHg (Mean)
	Baseline_8 AM	Change from Baseline at Week 12 _8 AM (n=61,63)	Baseline_12 Noon	Change from Baseline at Week 12_12 Noon (n=61,63)	Baseline_4 PM	Change from Baseline at Week 12_4 PM (n=61,63)
DuoTrav®	22.0	-4.5	20.3	-2.3	19.8	-2.4
LUMIGAN® RC	22.0	-2.7	20.6	-1.9	19.8	-1.3

Intervention	mmHg (Mean)
	Baseline_ 8 AM	Change from Baseline at Week 6 _8 AM (n=66,64)	Baseline_12 Noon	Change from Baseline at Week 6_12 Noon (n=66,64)	Baseline_4 PM	Change from Baseline at Week 6_4 PM (n=66,64)
DuoTrav®	22.0	-4.8	20.3	-2.8	19.8	-2.9
LUMIGAN® RC	22.0	-2.8	20.6	-2.1	19.8	-1.5

travoprost

Description

Cross-References

Synonyms (91)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Dosage Studied

Roles (5)

Drug Classes (3)

Protein Targets (4)

Inhibition Measurements

Biological Processes (41)

Molecular Functions (24)

Ceullar Components (17)

Bioassays (19)

Research

Studies (439)

Market Indicators

Research Demand Index: 82.44

Study Types

Clinical Trials (134)

Trial Overview

Trial Outcomes

Mean Intraocular Pressure

Tolerability - Conjunctival Hyperemia

Intraocular Pressure (IOP)

Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment

Intra Ocular Pressure (IOP)

Adherence

Comfort Immediately After Dosing

Change From Baseline in Tear Break-Up Time (TBUT) at Month 3

Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3

Change From Baseline in Corneal Staining With Fluorescein at Month 3

Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

Percentage of Patients With Corneal Fluorescein Staining Score = 0

The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)

Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year

Mean IOP (Intraocular Pressure)

Percentage of Patients With Corneal Fluorescein Staining Score = 0

Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

Number of Patients With Peripheral Anterior Synechiae (PAS)

Mean Intraocular Pressure (IOP)

Mean IOP Change From Baseline at 9 AM

Mean IOP Change at 4 PM

Week 12 - Mean IOP At 4 PM

Mean Intraocular Pressure (IOP) at 9 AM

Ocular Surface Disease Index Score

Intraocular Pressure

Corneal Staining Score

Conjunctival Hyperemia Score

Change in Tear Break up Time (TBUT)

Tear Production

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

Mean Intraocular Pressure at 4:00 pm

Mean Intraocular Pressure at 9:00 am

Mean Intraocular Pressure at 11:00 am

Mean Intraocular Pressure (IOP) at 10:00 AM

Mean Intraocular Pressure (IOP) at 12:00 PM

Mean Intraocular Pressure (IOP) at 2:00 PM

Mean Intraocular Pressure (IOP) at 4:00 PM

Mean Intraocular Pressure (IOP) at 6:00 PM

Mean Intraocular Pressure (IOP) at 8:00 PM

Mean Intraocular Pressure (IOP) at 8:00 AM

IOP Change From Baseline at 8 PM on Day 5

Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5

Mean Conjunctival Hyperemia at Week 12

Mean Corneal Staining With Fluorescein at Week 12

Mean Tear Break Up Time (TBUT) at Week 12

Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12

Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)

Mean Change From Baseline in IOP at Week 4

Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12

Corneal Fluorescein Staining Score

Intervention	ng/mL (Mean)
	Overall (n=11)	2 mo to < 3 years (n=2)	3 to <12 years (n=6)	12 to <18 years (n=3)
Travoprost	0.0256	0.0471	0.0258	0.0109

Intervention	hours (Mean)
	Overall (n=11)	2 mo to <3 years (n=2)	3 to <12 years (n=6)	12 to <18 years (n=3)
Travoprost	0.42	0.34	0.46	0.39

Intervention	ng*hr/mL (Mean)
	Overall (n=6)	2 mo to <3 years (n=2)	3 to <12 years (n=4)
Travoprost	0.0116	0.0101	0.0123

Intervention	mmHg (Mean)
	Baseline (Day 0)	Change from Baseline at Month 6, n=46,43
LUMIGAN	24.59	-7.35
TRAVATAN	24.66	-7.61

Intervention	mmHg (Mean)
	Change from Baseline at Week 6, n=46,46	Change from Baseline at Month 3, n=46,44
LUMIGAN	-7.02	-7.82
TRAVATAN	-7.50	-7.96

Intervention	units on a scale (Mean)
	Baseline (Day 0)	Change from Baseline at Month 3, n=44,43	Change from Baseline at Month 6, n=44,42
LUMIGAN	10.6	0.0	1.7
TRAVATAN	14.6	-0.3	0.4

Intervention	participants (Number)
	Baseline, Grade 0	Baseline, Grade 1	Baseline, Grade 2	Month 3, -1 Grade Change from Baseline	Month 3, 0 Grade Change from Baseline	Month 3, +1 Grade Change from Baseline	Month 3, +2 Grade Change from Baseline	Month 6, -1 Grade Change from Baseline	Month 6, 0 Grade Change from Baseline	Month 6, +1 Grade Change from Baseline	Month 6, +2 Grade Change from Baseline
LUMIGAN	39	9	1	6	33	5	0	7	26	9	1
TRAVATAN	44	6	0	6	36	3	1	4	31	11	0

Intervention	percentage of participants (Number)
	Week 6, n=46,46	Month 3, n=46,44	Month 6, n=46,43
LUMIGAN	56.5	70.5	67.4
TRAVATAN	69.6	71.7	73.9

Intervention	percentage of oxygenation (Mean)
Normal Control	60
Glaucoma Suspect	60
Newly Diagnosed Glaucoma	60

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Week 12 at 8 AM	Week 12 at 12 PM	Week 12 at 4 PM
Bimatoprost 0.01% and Hypromellose 0.3%	16.4	16.0	16.5
Travatan 0.004% and Timolol 0.5%	15.1	15.0	14.5